Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Allakos Inc (ALLK)ALLK

Upturn stock ratingUpturn stock rating
Allakos Inc
$0.64
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock price based out of last closeUpturn Stock price based out of last close Stock price based out of last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/02/2024: ALLK (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Upturns

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Profit: -68.75%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 32
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 10/02/2024
Type: Stock
Today’s Advisory: PASS
Profit: -68.75%
Avg. Invested days: 32
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/02/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 55.44M USD
Price to earnings Ratio -
1Y Target Price 2.77
Dividends yield (FY) -
Basic EPS (TTM) -2.35
Volume (30-day avg) 364823
Beta 1.15
52 Weeks Range 0.54 - 3.40
Updated Date 10/1/2024
Company Size Small-Cap Stock
Market Capitalization 55.44M USD
Price to earnings Ratio -
1Y Target Price 2.77
Dividends yield (FY) -
Basic EPS (TTM) -2.35
Volume (30-day avg) 364823
Beta 1.15
52 Weeks Range 0.54 - 3.40
Updated Date 10/1/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -49.29%
Return on Equity (TTM) -121.54%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -27499902
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.5
Shares Outstanding 88850704
Shares Floating 59217223
Percent Insiders 2.33
Percent Institutions 88.1
Trailing PE -
Forward PE -
Enterprise Value -27499902
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.5
Shares Outstanding 88850704
Shares Floating 59217223
Percent Insiders 2.33
Percent Institutions 88.1

Analyst Ratings

Rating 3.12
Target Price 9.92
Buy 2
Strong Buy -
Hold 5
Sell 1
Strong Sell -
Rating 3.12
Target Price 9.92
Buy 2
Strong Buy -
Hold 5
Sell 1
Strong Sell -

AI Summarization

Allakos Inc.: A Comprehensive Overview (as of November 2023)

Company Profile

Detailed History and Background:

  • Founded in 2007 in Redwood City, California, by Dr. Michael Dillon and Dr. Adrian Hepner.
  • Initial focus on developing therapies for chronic inflammatory diseases like allergic asthma.
  • 2015: Completed a pivotal Phase III study for AK002 in atopic dermatitis.
  • 2016: Public offering on NASDAQ, raising $97 million.
  • 2023: Ongoing Phase III program for lirentelimab (AK002) in eosinophilic esophagitis (EoE).

Core Business Areas:

  • Developing therapeutic antibodies targeting the immune system.
  • Focus on inflammatory and allergic diseases like EoE, atopic dermatitis, and asthma.
  • Utilizing a proprietary discovery platform – the Th2-inflammation Antibody Discovery and Development (Th2-iADD) platform.

Leadership Team:

  • President & CEO: Dr. Maurice A. Zauderer, extensive experience in the pharmaceutical industry, including leadership at Genentech and Roche.
  • Chief Medical Officer: Dr. Michael A. DeBaun, former VP Clinical Development & Medical Affairs at Dyax Corp.
  • Other key executives with expertise in research, development, finance, and legal.

Top Products and Market Share

Top Products:

  • Lirnelimab (AK002): Anti-IL-13 monoclonal antibody, currently in Phase III trials for EoE and atopic dermatitis.
  • Eniflamilast (AK001): Pan-PDE4 inhibitor, previously in development for asthma but discontinued due to safety concerns.

Market Share:

  • Lirnelimab has no direct competitors as it targets a novel pathway in EoE.
  • For atopic dermatitis, competitors include dupilumab (Dupixent) by Regeneron and Sanofi, and tralokinumab (Adtralza) by LEO Pharma.

Product Performance and Market Reception:

  • Early data from Phase III studies for EoE show lirentelimab to be safe and effective, with potential to be a first-in-class treatment.
  • Initial market response has been positive, with analysts expecting strong sales potential upon approval.

Total Addressable Market

EoE: Estimated to be around 1 million patients in the U.S. and EU. Atopic Dermatitis: Affects around 10-20% of children and 1-3% of adults globally.

Financial Performance

Recent Financial Statements:

  • Revenue: Primarily from collaborations and grants.
  • Net Income: Currently negative due to R&D expenses.
  • Profit Margins: Not yet profitable.
  • EPS: Negative, reflecting R&D investments.

Year-over-Year Performance:

  • Revenue has been increasing steadily due to progress in clinical trials and partnerships.
  • Net losses have also been increasing, reflecting R&D investments.

Cash Flow and Balance Sheet:

  • Current cash and equivalents: $218 million as of June 2023.
  • Strong cash position to support ongoing clinical trials.

Dividends and Shareholder Returns

Dividend History:

  • No dividend history as the company is not yet profitable.

Shareholder Returns:

  • Stock price has fluctuated significantly based on clinical trial results and market sentiment.
  • Overall, shareholder returns have been positive since the IPO.

Growth Trajectory

Historical Growth:

  • Revenue has grown significantly in recent years due to clinical progress and collaborations.
  • Net losses have also increased due to R&D investments.

Future Growth Projections:

  • Analysts expect strong revenue growth upon potential approval and commercialization of lirentelimab.
  • Future growth will depend on clinical trial outcomes, regulatory approvals, and market adoption.

Market Dynamics

Industry Overview:

  • Growing market for treatments of inflammatory and allergic diseases.
  • Increasing demand for novel and effective therapies with better safety profiles.
  • Intense competition among pharmaceutical companies.

Company Positioning:

  • Allakos holds a first-mover advantage with lirentelimab as a potential first-in-class treatment for EoE.
  • The company needs to demonstrate the safety and efficacy of its products to achieve long-term success.

Competitors

Key Competitors:

  • For EoE: None currently, but potential competitors include companies developing anti-IL-5 therapies.
  • For atopic dermatitis: Regeneron, Sanofi, LEO Pharma, and others.

Market Share Percentages:

  • Lirnelimab: No market share yet, as it is not yet approved.
  • Competitors: Dupixent (Dupilumab) holds a significant market share in atopic dermatitis.

Competitive Advantages:

  • First-mover advantage with lirentelimab for EoE.
  • Proprietary Th2-iADD platform with potential for further pipeline development.

Disadvantages:

  • Limited commercial experience.
  • Dependence on a single drug candidate for near-term growth.

Potential Challenges and Opportunities

Key Challenges:

  • Demonstrating safety and efficacy of lirentelimab in ongoing clinical trials.
  • Obtaining regulatory approvals for lirentelimab in target markets.
  • Achieving market adoption and competing with established players in atopic dermatitis.

Potential Opportunities:

  • Expanding the use of lirentelimab into other indications beyond EoE and atopic dermatitis.
  • Developing additional product candidates from the Th2-iADD platform.
  • Partnering with larger pharmaceutical companies for commercialization and distribution.

Recent Acquisitions

No acquisitions have been made by Allakos Inc. in the past 3 years.

AI-Based Fundamental Rating

8 out of 10:

Strengths:

  • Promising late-stage drug candidate with first-mover advantage.
  • Strong cash position to support ongoing operations.
  • Experienced leadership team with industry expertise.

Weaknesses:

  • Limited commercial experience and dependence on a single drug candidate.
  • Intense competition in the targeted markets.

Overall, Allakos Inc. is a promising company with a strong pipeline and potential for significant growth upon commercialization of lirentelimab. However, it faces challenges in a competitive market and needs to execute successfully on its clinical and commercialization plans.

Sources and Disclaimers

Sources:

Disclaimer:

This information is provided for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Allakos Inc

Exchange NASDAQ Headquaters San Carlos, CA, United States
IPO Launch date 2018-07-19 CEO & Director Dr. Robert Alexander Ph.D.
Sector Healthcare Website https://www.allakos.com
Industry Biotechnology Full time employees 131
Headquaters San Carlos, CA, United States
CEO & Director Dr. Robert Alexander Ph.D.
Website https://www.allakos.com
Website https://www.allakos.com
Full time employees 131

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​